Skip to main content

Table 1 STOPP screening criteria [22]

From: A comparison of estimated drug costs of potentially inappropriate medications between older patients receiving nurse home visit services and patients receiving pharmacist home visit services: a cross-sectional and propensity score analysis

  STOPP criteria
A. Cardiovascular system
1 Digoxin at a long-term dose >125 mg/d with impaired renal function
2 Loop diuretic as first-line monotherapy for hypertension or for dependent ankle edema only
3 Thiazide diuretic with a history of gout
4 Noncardioselective b-blocker with chronic obstructive pulmonary disease
5 b-blocker in combination with verapamil
6 Use of diltiazem or verapamil with New York Heart Association class 3 or 4 heart failure
7 Calcium-channel blockers with chronic constipation
8 Use of aspirin and warfarin in combination without histamine H2 receptor antagonist
(except cimetidine) or proton pump inhibitor
9 Dipyridamole as monotherapy for cardiovascular secondary prevention
10 Aspirin with no history of coronary, cerebral or peripheral vascular symptoms
  or occlusive arterial event or with a past history of peptic ulcer disease
  without histamine H2 receptor antagonist or proton pumpinhibitor or at dose >150 mg/d
  or to treat dizziness not clearly attributed to cerebrovascular disease
11 Warfarin for first, uncomplicated deep venous thrombosis for longer than 6-month duration
  or for first, uncomplicated pulmonary embolus for longer than 12-month duration
12 Aspirin, clopidogrel, dipyridamole, or warfarin with concurrent bleeding disorder
B. CNS and psychotropic drugs
1 Tricyclic antidepressants with dementia or with glaucoma or with cardiac conductive abnormalities
  or with constipation or with prostatism or prior history of urinary retention or with an opiate
  or calcium-channel blocker
2 Long-term (>3 month) use of long-acting benzodiazepines, and with long-acting metabolites
3 Long-term (>1 month) neuroleptics as long-term hypnotics or in those with parkinsonism
4 Phenothiazines in patients with epilepsy
5 Anticholinergics to treat extrapyramidal side effects of neuroleptic medications
6 Selective serotonin reuptake inhibitors with a history of clinically significant hyponatremia
  (noniatrogenic hyponatremia <130 mmol/L within the previous 2 months)
7 Prolonged use (>1 week) of first-generation antihistamines
C. Gastrointestinal system
1 Diphenoxylate, loperamide or codeine phosphate for treatment of diarrhea of unknown cause
  or severe infective gastroenteritis
2 Prochlorperazine or metoclopramide with parkinsonism
3 Proton pump inhibitors for peptic ulcer disease at full therapeutic dosage for >8 weeks
4 Anticholinergic antispasmodic drugs with chronic constipation
D. Respiratory system
1 Theophylline as monotherapy for chronic obstructive pulmonary disease
2 Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy
  in moderate-to-severe chronic obstructive pulmonary disease
3 Nebulized ipratropium with glaucoma
E. Musculoskeletal system
1 NSAID with history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent
  histamine H2 receptor antagonist, proton pump inhibitor, or misoprostol
2 NSAID with moderate-to-severe hypertension or with heart failure
3 Long-term use of NSAID (>3 months) for relief of mild joint pain in osteoarthritis
4 Warfarin and NSAID together
5 NSAID with chronic renal failure
6 Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthritis
  or osteoarthritis
7 Long-term NSAID or colchicine for chronic treatment of gout where there is
  no contraindication to allopurinol
F. Urogenital system
1 Bladder antimuscarinic drugs with dementia or with chronic glaucoma
  or with chronic constipation or with chronic prostatism
2 a-blockers in males with frequent incontinence
3 a-blockers with long-term urinary catheter in situ (>2 months)
G. Endocrine system
1 Glibenclamide or chlorpropamide with type 2 diabetes mellitus
2 b-blockers in those with diabetes mellitus and frequent hypoglycemic episodes
3 Estrogens with a history of breast cancer or venous thromboembolism
4 Estrogens without progestogen in patients with intact uterus
H. Drugs that adversely affect those prone to falls (at least 1 fall in past 3 months)
1 Benzodiazepines
2 Neuroleptic drugs
3 First-generation antihistamines
4 Vasodilator drugs known to cause hypotension in those with persistent postural hypotension
5 Long-term opiates in those with recurrent falls
I. Analgesic drugs
1 Use of long-term powerful opiates as first-line therapy for mild-to-moderate pain
2 Regular opiates for more than 2 weeks in those with chronic constipation
  without concurrent use of laxatives
3 Long-term opiates in those with dementia unless indicated for palliative care
  or management of moderate-to-severe chronic pain syndrome
J. Duplicate drug classes
1 Any regular duplicate drug class prescription, such as two concurrent opiates, NSAIDs,
  serotonin-specific reuptake inhibitors, loop diuretics, and ACE inhibitors